Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
IRVINE, Calif., April 27, 2017 -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces that it will release financial results for the three months ended March 31, 2017 after market close on Thursday, May 4, 2017. CombiMatrix management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss those results and answer questions.
| Live Call: | U.S.: | (866) 634-2258 |
| International: | (330) 863-3454 | |
| Live Webcast: | http://investor.combimatrix.com/events.cfm The webcast replay will be archived for 30 days | |
| Replay: | U.S.: | (855) 859-2056 |
| International: | (404) 537-3406 | |
| Passcode: | 10856966 | |
| The telephone replay will be available for seven days |
About CombiMatrix Corporation
CombiMatrix Corporation provides best-in-class molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. Our testing focuses on advanced technologies, including single nucleotide polymorphism chromosomal microarray analysis, next-generation sequencing, fluorescent in situ hybridization and high resolution karyotyping. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.
Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation (949) 753-0624 Investor Contact: LHA Jody Cain (310) 691-7100 [email protected]
